Immunological antibody complex, its preparation and its use
Patent 4868109 Issued on September 19, 1989. Estimated Expiration Date: 
September 19, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 19, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesAntibody fragment compositions and process Immunoglobulin half-molecules and process for producing hybrid antibodies Pre-precipitated double antibody immunoassay method Specific binding assay conjugate with spaced-apart receptors Target specific cross-linked heteroantibodies Patent #: 4676980 InventorApplicationNo. 06/855688 filed on 04/25/1986US Classes:435/7.1, Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay424/136.1, Bispecific or bifunctional, or multispecific or multifunctional, antibody or fragment thereof424/178.1, CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL435/28, Involving peroxidase435/5, Involving virus or bacteriophage435/7.2, Involving a micro-organism or cell membrane bound antigen or cell membrane bound receptor or cell membrane bound antibody or microbial lysate435/7.21, Animal cell435/7.23, Tumor cell or cancer cell435/7.24, Leukocyte (e.g., lymphocyte, granulocyte, monocyte, etc.)435/7.25, Erythrocyte435/7.32, Bacteria or actinomycetales435/972, MODIFIED ANTIBODY (E.G., HYBRID, BIFUNCTIONAL, ETC.)436/518, INVOLVING AN INSOLUBLE CARRIER FOR IMMOBILIZING IMMUNOCHEMICALS436/519, Carrier is a biological cell or cell fragment436/520, Red blood cell436/536, INVOLVING IMMUNE COMPLEX FORMED IN LIQUID PHASE436/547, INVOLVING PRODUCTION OR TREATMENT OF ANTIBODY530/388.2, Binds microorganism or normal or mutant component or product thereof (e.g., animal cell, cell-surface antigen, secretory product, etc.)530/388.25, Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.)530/388.26, Binds enzyme530/388.7, Binds hematopoietic cell or component or product thereof (e.g., erythrocyte granulocyte, macrophage, monocyte, platelet, myelogenous leukemia cell, bone marrow stem cell, granulocytic cell-surface antigen, hemoglobin, thrombospondin, glycophorin, etc.)530/402, Chemical modification or the reaction product thereof, e.g., covalent attachment or coupling, etc.530/403Protein is identified as an antigen, e.g., immunogenic carriers, etc.ExaminersPrimary: Rosen, SamAttorney, Agent or FirmInternational ClassesC07K 16/46 (20060101)G01N 33/535 (20060101) G01N 33/531 (20060101) G01N 33/563 (20060101) Foreign Application Priority Data1985-04-29 NLAbstractThe invention relates to an immunological complex of two antibodies of a first animal species, e.g. mouse antibodies, which have been conjugated to form a cyclic tetramer with two monoclonal antibodies of a second animal species, e.g. rat monoclonal antibodies, directed against the Fc-fragment of the antibodies of the first animal species.Preferably, the complex is bifunctional, that is to say, that it contains two different antibodies of the first animal species, one of which is preferably directed to a detectable substance, such as an enzyme, e.g. peroxidase, and the other is directed to any desired antigen. A tetrameric complex of this kind may be used as a labelled antibody in immunoassays.Further, the invention relates to processes for preparing the complexes and for using the complexes in immunological reactions. Finally, the invention relates to drugs containing a complex according to the invention, as the complexes may be used to direct certain active principles to target cells.Other References
|
| ||||||||||||||
